| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.76 | 219.7% | 63.0% |
| Total Income | 1.76 | 219.7% | 63.0% |
| Expenditure | 14.63 | 9.1% | 125.4% |
| PBT | 0.16 | 98.7% | 101.2% |
| Net Profit | 0.16 | 98.7% | 99.9% |
| OPM | — | ||
| NPM | 8.91% | 91.09pp | |
| EPS | 0.04 | 98.7% | 99.9% |
Kyntra Bio Reports Q3 2026 Financial Results and Provides Business Update
17 Nov 2026 · 17 Nov, 3:07 am
Summary
Kyntra Bio reported third quarter 2026 revenue of $1.8 million, up from $1.1 million in the prior year. The company achieved net income from continuing operations of $0.2 million, or $0.04 per share, a substantial turnaround from a net loss of $13.1 million in Q3 2025. Management highlighted the strategic decision to discontinue FG-3246 and FG-3180 development, which is expected to save over $20 million in operating expenses, and the planned initiation of the pivotal Phase 3 roxadustat trial in Q1 2027, contingent on a strategic partnership or capital raise. The company ended the quarter with $44.1 million in cash and cash equivalents, providing runway into 2028.
Key Highlights
- 1
Total revenue from continuing operations for the third quarter of 2026 was $1.8 million, an increase from $1.1 million in the third quarter of 2025.
- 2
Net income from continuing operations for the third quarter of 2026 was $0.2 million, or $0.04 per share, a significant improvement from a net loss of $13.1 million, or $3.25 per share, in the prior year.
- 3
The company reported $44.1 million in cash, cash equivalents, investments, and accounts receivable as of September 30, 2026, with a cash runway extending into 2028.
- 4
Kyntra Bio completed a restructuring of its royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining.
- 5
The pivotal Phase 3 trial of roxadustat for anemia in LR-MDS patients is planned for Q1 2027, subject to strategic partnership or capital raise.
- 6
Development of FG-3246 and FG-3180 has been discontinued due to insufficient efficacy, expected to reduce operating expenses by over $20 million in 2027 and 2028.
Management Comments
Thane Wettig
Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial. The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant. Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.
Informational and educational content only. Not investment advice.